TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02132091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 IU Vitamin E
Description: once each day in morning; oral pill form
Study: NCT03674294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palonosetron
Description: Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
Study: NCT01505140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole walnuts
Description: 75 gm whole walnuts per day will be consumed with usual Western style diet
Study: NCT01116804

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI of the liver before start of treatment
Description: MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI after treatment
Description: MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET-scan before treatment start
Description: PET-scan with 2 tracers is performed before treatment start

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET scan after treatment
Description: PET-scan with 2 tracers is repeated 4 weeks following start of treatment
Study: NCT03239262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concomitant Mapping and Radiofrequency Ablation
Description: Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure\>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention was performed in patients without ganglionated plexi.
Study: NCT03369210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: red blood cell transfusion trigger
Description: patients receive a RBC unit with different target ranges for the post-transfusion Hb levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion trigger
Description: patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
Study: NCT01259921

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: neurofeedback
Description: Operant conditioning of the EEG provided by computer reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback
Description: Operant conditioning of the EEG provided by computer reinforcement.
Study: NCT01895634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rev-01
Description: Treatment arm patients have used Rev-01 at least once
Study: NCT01706120

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: • Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: • Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: • Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
Study: NCT02245880

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILMA
Description: handling of the device till the optimal ventilation achieved
Study: NCT04247529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to conflicting health information
Description: At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No exposure to conflicting health information
Description: At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
Study: NCT04028024

Intervention type: DRUG
Group type: OTHER
Intervention: Ulinastatin
Description: Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
Study: NCT02204059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hMAb BIWA 4
Study: NCT00776581

Intervention type: PROCEDURE
Intervention: CSEA with PCA
Description: Records regarding combined spinal-epidural analgesia with patient-controlled pump

Intervention type: PROCEDURE
Intervention: CSEA with IBI
Description: Records regarding combined spinal-epidural analgesia with intermittent bolus injection

Intervention type: PROCEDURE
Intervention: EA with PCA
Description: Records regarding epidural analgesia with patient-controlled pump

Intervention type: PROCEDURE
Intervention: EA with IBI
Description: Records regarding epidural analgesia with intermittent bolus injection
Study: NCT03714789

Intervention type: OTHER
Intervention: Blood and spent dialysate collection
Description: A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.

Intervention type: OTHER
Intervention: Blood and spent dialysate collection
Description: A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.

Intervention type: OTHER
Intervention: Blood and spent dialysate collection
Description: A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
Study: NCT01869452

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: therapeutic education
Description: knowledge of disease, risk factors, diet, medication, alert symptoms

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: therapeutic education
Description: knowledge of disease, risk factors, diet, medication, alert symptoms

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: therapeutic education
Description: knowledge of disease, risk factors, diet, medication, alert symptoms
Study: NCT04062006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
Study: NCT00118040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given orally
Study: NCT03722667

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Technology-based Component
Description: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TechSupport
Description: The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence.
Study: NCT00926783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFAE ablation
Description: CFAE ablation (targeted vs. generalized)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFAE ablation
Description: CFAE ablation (targeted vs. generalized)
Study: NCT04063423

Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
Study: NCT00521534

Intervention type: DEVICE
Intervention: CRT with atrial overdrive pacing
Description: Both groups receive CRT, one group receives atrial overdrive pacing
Study: NCT02132091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1000 mg Vitamin C
Description: 500mg twice each day; morning and evening; oral pill form
Study: NCT04525417

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AAZ Covid-19 rapid test
Description: To assess the immune status

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AAZ Covid-19 rapid test
Description: To assess the immune status
Study: NCT01824641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eliminate aspiration catheter
Description: Eliminate aspiration catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional primary angioplasty
Description: Primary angioplasty without thrombus aspiration
Study: NCT00133952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01548651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
Study: NCT00080808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil (E1)
Description: Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
Study: NCT00056966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANTI-CD45
Description: 400ug/kg Day-5 through Day-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Description: Day -8 through Day -6 Dosed per Institutional SOP
Study: NCT00118040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
Study: NCT02865928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine HCl
Description: Ultrasound guided serratus plane block with bupivicaine
Study: NCT00080808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine mesylate
Description: Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine mesylate
Description: Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: Oral sildenafil as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: Oral sildenafil as needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Unilateral cavernous nerve sparing radical retropubic prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Unilateral cavernous nerve sparing radical retropubic prostatectomy
Study: NCT04985097

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Implantation of trifocal diffractive intraocular lenses
Description: Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of trifocal diffractive intraocular lenses
Description: Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
Study: NCT06365398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium Injection
Description: In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No heparinization
Description: No additional heparin was administered via the sheath or arterial route in the no heparinization group.
Study: NCT03530878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip Arthroscopy
Description: Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
Study: NCT04829396

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre mixture
Description: The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
Study: NCT03129100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03752632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinplicity with tourniquet
Description: Veinplicity will be used with a tourniquet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: A tourniquet alone will be used.
Study: NCT01413529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART to HAART
Description: The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: adherence counseling with the addition of smartphone control
Description: Participants will receive adherence counseling with the addition of smartphone control.